JSPR net incomeQ2 2026-$2.76M
JSPR net income was -$2.76M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$26.72M a year earlier. For the full fiscal 2025 it was -$75.80M, compared with -$71.27M in fiscal 2024.
Jasper Therapeutics Inc. (JSPR) financials
For the twelve months ended Jun 30, 2026, Jasper Therapeutics Inc. reported -$31.77M of net income.
- Net income, TTM
- -$31.77M
- Cash
- $7.31M
- Market cap
- $18.2M
FY2020FY2025
JSPR revenue and earnings growth
JSPR EPSQ2 2026-$0.10
JSPR diluted EPS was -$0.10 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$3.95, compared with -$4.89 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cost of revenue | $41.63M | $34.27M | - | - | - | - |
| Research and development | $63.10M | $55.82M | $51.78M | $34.63M | $25.42M | $15.88M |
| Selling, general and admin | $20.78M | $20.42M | $17.08M | $16.57M | $11.41M | $4.80M |
| Operating income | -$83.88M | -$76.24M | -$68.86M | -$51.20M | -$36.83M | -$20.68M |
| Pre-tax income | - | - | - | - | - | -$6.44M |
| Income tax | - | $2.0K | $2.0K | - | - | $38.5K |
| Net income | -$75.80M | -$71.27M | -$64.47M | -$37.69M | -$30.64M | -$31.67M |
| EPS, basic | -$3.95 | -$4.89 | -$6.18 | -$10.33 | -$26.90 | -$51.70 |
| EPS, diluted | -$3.95 | -$4.89 | -$6.18 | -$10.33 | -$26.90 | -$51.70 |
| Diluted shares | 19.2M | 14.6M | 10.4M | 3.6M | 1.1M | 612,589.7 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $28.69M | $72.05M | $87.30M | $38.67M | $85.05M | $20.18M |
| Current assets | $34.65M | $75.81M | $88.94M | $41.73M | $87.83M | $20.68M |
| Total assets | $35.78M | $79.90M | $94.89M | $48.36M | $93.65M | $23.36M |
| Current liabilities | $13.20M | $15.24M | $12.37M | $7.07M | $8.02M | $4.01M |
| Total liabilities | $31.63M | $18.23M | $16.45M | $12.37M | $24.14M | $14.65M |
| Shareholders' equity | $4.15M | $61.67M | $78.44M | $35.99M | $69.52M | -$35.13M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$77.16M | -$62.60M | -$52.07M | -$45.86M | -$33.68M | -$18.27M |
| Investing cash flow | $5.0K | -$532.0K | -$267.0K | -$576.0K | -$2.43M | $198.3K |
| Financing cash flow | $34.21M | $47.88M | $100.97M | $55.0K | $100.97M | $11.29M |
| Stock-based compensation | $6.71M | $6.62M | $5.21M | $4.09M | $1.05M | $1.21M |
| Depreciation and amortization | $1.06M | $1.37M | $1.11M | $975.0K | $377.0K | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $3.58M | $3.62M | $6.76M | $9.35M | $15.77M | $9.76M | $13.17M | $8.78M | - | - | - | - |
| Research and development | $5.13M | $5.81M | $11.36M | $14.39M | $21.20M | $16.16M | $19.77M | $14.46M | $11.30M | $10.30M | $13.84M | $14.85M |
| Selling, general and admin | $4.07M | $5.14M | $4.48M | $4.78M | $5.88M | $5.64M | $5.51M | $5.43M | $4.70M | $4.77M | $3.89M | $4.51M |
| Operating income | -$9.21M | -$10.95M | -$15.84M | -$19.17M | -$27.08M | -$21.80M | -$25.29M | -$19.89M | -$15.99M | -$15.07M | -$17.73M | -$19.36M |
| Net income | -$2.76M | -$1.17M | -$9.10M | -$18.74M | -$26.72M | -$21.24M | -$24.32M | -$18.64M | -$14.58M | -$13.73M | -$16.58M | -$17.54M |
| EPS, basic | -$0.10 | -$0.04 | - | -$1.13 | -$1.74 | -$1.41 | -$1.65 | -$1.24 | -$0.97 | -$1.03 | - | -$1.60 |
| EPS, diluted | -$0.10 | -$0.04 | - | -$1.13 | -$1.74 | -$1.41 | -$1.65 | -$1.24 | -$0.97 | -$1.03 | - | -$1.60 |
| Diluted shares | 28.7M | 28.7M | - | 16.6M | 15.3M | 15.0M | - | 15.0M | 15.0M | 13.3M | - | 11.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.31M | $14.14M | $28.69M | $50.90M | $39.93M | $49.22M | $72.05M | $92.92M | $107.24M | $118.89M | $87.30M | $104.28M |
| Short-term investments | - | - | - | - | - | - | - | - | - | - | - | $3.40M |
| Current assets | $11.57M | $20.29M | $34.65M | $54.56M | $42.97M | $53.17M | $75.81M | $94.81M | $108.68M | $120.31M | $88.94M | $105.22M |
| Total assets | $11.80M | $21.18M | $35.78M | $57.47M | $46.47M | $57.60M | $79.90M | $99.41M | $113.93M | $125.96M | $94.89M | $110.41M |
| Current liabilities | $7.84M | $9.00M | $13.20M | $21.04M | $20.50M | $12.33M | $15.24M | $12.46M | $10.07M | $8.92M | $12.37M | $11.91M |
| Total liabilities | $10.39M | $17.78M | $31.63M | $45.90M | $22.96M | $15.35M | $18.23M | $15.73M | $13.62M | $12.73M | $16.45M | $16.27M |
| Shareholders' equity | $1.41M | $3.40M | $4.15M | $11.57M | $23.50M | $42.24M | $61.67M | $83.68M | $100.31M | $113.23M | $78.44M | $94.13M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.92M | -$14.55M | -$21.87M | -$17.00M | -$15.45M | -$22.84M | -$21.13M | -$14.05M | -$11.68M | -$15.74M | -$16.48M | -$11.98M |
| Investing cash flow | - | - | $0 | $0 | $1.0K | $4.0K | -$76.0K | -$274.0K | -$157.0K | -$25.0K | -$230.0K | $0 |
| Financing cash flow | - | - | -$340.0K | $28.39M | - | - | $345.0K | $9.0K | $181.0K | $47.35M | -$271.0K | $36.0K |
| Stock-based compensation | $764.0K | $423.0K | $1.66M | $1.42M | $1.82M | $1.81M | $1.97M | $2.00M | $1.48M | $1.17M | $1.16M | $1.40M |
| Depreciation and amortization | $21.0K | $21.0K | $290.0K | $229.0K | $258.0K | $279.0K | $245.0K | $500.0K | $300.0K | $288.0K | $283.0K | $300.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.47 | 2.26 | 2.62 | 2.59 | 2.10 | 4.31 | 4.98 | 7.61 | 10.79 | 13.49 | 7.19 | 8.84 |
Source: XBRL data Jasper Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Mar 5, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
JSPR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| JSPR | - | - | -$31.77M | - | $18.2M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
JSPR FAQ
4 questionsIs JSPR profitable?
No. Jasper Therapeutics Inc. reported a net loss of $31.77M for the twelve months ended Jun 30, 2026.How much cash and debt does JSPR have?
Jasper Therapeutics Inc. reported $7.31M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did JSPR last report financial results?
The latest statements here come from Jasper Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this JSPR financial data come from?
Quantisnow builds these statements from the structured XBRL data Jasper Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.